Purdue Develops New Strategy for Drug Discovery

Posted: Updated:
Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials. Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials.

Research scientists often confront the “valley of death”—the gaping hole that exists between laboratory discoveries and their transformation into new medical treatments and products. And the most lethal factor for most researchers is money. However, Purdue University is blazing an unusual trail to help make ends meet in translational research. Rather than rely on traditional sources, the university has formed a not-for-profit startup to take discoveries from the lab up to Phase 1 human clinical trials.

“We develop a lot of drugs [at Purdue]; there aren’t many academic institutions or cancer centers [in our position]—with 14 of their drugs that are synthesized at their own institution in human clinical trials,” says Purdue Center for Cancer Research Robert Wallace Miller Director Dr. Tim Ratliff. “It’s a real strength here, and we want to improve and speed the process.”

Translating basic research into life-changing treatments is one initiative of Purdue Moves, a program that involves 10 university initiatives designed to enhance research, education and the school’s global impact.

Purdue’s Center for Cancer Research is one of only seven basic science research centers in the country designated by the National Cancer Institute. While Ratliff describes the center as a very efficient entity that can “move things forward in a rapid manner,” the process is still slower than scientists like.

Researchers typically rely on external funding from government sources to help them uncover a discovery, but beyond that, the money often dries up.

“[Government sources] don’t fund drugs from the discovery through all these routine processes you have to go through to get that drug ready to go into clinical trials,” says Ratliff. “You have to take these drugs and develop them, so that we understand the toxicities associated with them, their distribution in the body and other fundamental things before we get into the clinic.”

This is when most scientists encounter the “valley of death,” but Purdue believes it can finance the very expensive process with its newly formed Boilermaker Health Innovations, a not-for-profit startup that represents a unique way to fund the gap. Boilermaker Health believes it will be much speedier than the traditional route of forming for-profit companies that aim to attract investments to reach human clinical trials.

Once Boilermaker Health has funded a scientist through early research, Ratliff says it will spin-off a for-profit company to develop the compound and take it through U.S. Food and Drug Administration approval or sell the drug to a large pharmaceutical company.

“As we develop these drugs from very early stages, we envision those drugs will gain value,” says Ratliff. “While we’re a not-for-profit company, that value will create a fund in Boilermaker Health that will allow us, over time, to become independent and support our cancer research and drug discovery very efficiently through the use of those funds.”

Ratliff acknowledges the unconventional model begs the question of how Boilermaker Health will get its first infusion of cash; he says it will rely on Purdue donors, federal funding agencies and private foundations. The Purdue Research Foundation is also matching each donation, up to a total of $1.3 million.

Additionally, Boilermaker Health is considering an alumni crowdfunding effort. The startup has already received a commitment of $175,000 and is “pushing hard” to collect more donations.

“Earning the match would give us $2.6 million, and that would be sufficient to move our first compound through pre-clinical analyses,” says Ratliff. “Once Boilermaker Health gets the drug through the proof of principle clinical trial, that will enable us to sell the product at a higher value, and that higher value will bring revenue back in. The money that we get back, we re-invest into drug discovery, amplifying our ability to move drugs through the valley of death.”

An external advisory committee is currently evaluating compounds in the Purdue pipeline to select the first for Boilermaker Health to “shepherd.” Leaders are hopeful the university’s unique strengths in drug discovery will also pave an unconventional path to patients.

Ratliff says there’s one question he gets the most about Boilermaker Health Innovations.
Ratliff says an external advisory committee will select the first compound that Boilermaker Health Innovations will “shepherd.”
  • Perspectives

    • A Pro Photographer Can Be Your Best Friend

      It's no surprise that an estimated 8.8 trillion photos were taken worldwide during 2018, given that most of us carry high-quality cameras in our phones. But shooting all those photos doesn't make us photographers. Digital technology has become a powerful equalizer in so many ways. Everyday people have access to tools that are far more sophisticated than what professionals had at their disposal a couple decades ago. High-school-age musicians can craft 24-track studio recordings in the...
    More

Events



  • Most Popular Stories

    • Chamber Unveils 'Best Places to Work'

      The Indiana Chamber of Commerce has released its list of the Best Places to Work in Indiana. This year's list features 125 companies throughout the state, including more than 40 that were not on the list last year. The chamber will unveil company rankings April 30 at an awards dinner at the Indiana Convention Center in downtown Indianapolis. Winners are sorted into four categories based on size. Out-of-state parent companies must have at least 15 full-time employees in Indiana to...

    • Lev Bringing Headquarters to Indy

      Marketing technology consulting firm Lev has announced plans to relocate its headquarters to Indianapolis. The company, which is currently based in Arizona, says it plans to hire 70 employees this year, part of a previously-announced effort to create up to 175 jobs by 2021. Lev has had a presence in Indianapolis for nearly three years and Chief Executive Officer Michael Burton says, since that time, the company has outgrown every space it has occupied in Indy. In an interview with...

    • Mixed-Use Project Proposed For Speedway Main Street

      A Fishers-based commercial real estate development firm is proposing an $8 million mixed-use development in Speedway. Rebar Development says the project would redevelop a section of Main Street that would include residential, office and retail space.

    • Amendment Makes Major Change to Hate Crimes Bill

      A bill that would allow for longer sentences for hate crimes is moving forward with a significant change. Our partners at WIBC report the Senate passed an amendment Tuesday that removed the list of individual groups that would be covered under the law. Originally, Senate Bill 12 said a sentence could be lengthened if someone convicted of a crime was found to have deliberately targeted someone based on factors including race, religion, and sexual orientation, among others.

    • The study came from the Climate Change Research Center in Purdue's Discovery Park.

      Study: Climate Change Could Cost Businesses Big

      Demand for cooling will increase, and homes and businesses will get more of their energy through natural gas and renewable resources as Indiana's climate warms. Those are the main findings from the latest Indiana Climate Change Impacts Assessment report, released by the Climate Change Research Center in Purdue's Discovery Park. The report suggests, while residential energy use will decrease by as much as 3 percent by mid-century, business energy use will increase by as much as...